A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT01412333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
Study identification
- NCT ID
- NCT01412333
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 835 participants
Conditions and interventions
Conditions
Interventions
- Interferon beta-1a Drug
- Ocrelizumab-matching placebo Drug
- Ocrelizumab Drug
- Interferon beta-1a-matching placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2011
- Primary completion
- May 11, 2015
- Completion
- Dec 29, 2022
- Last update posted
- Mar 7, 2024
2011 – 2022
United States locations
- U.S. sites
- 48
- U.S. states
- 21
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hope Research Institute | Phoenix | Arizona | 85050 | — |
| HonorHealth Neurology | Scottsdale | Arizona | 85251 | — |
| Territory Neurology and Research Institute | Tucson | Arizona | 85704 | — |
| Collaborative Neuroscience Research, LLC | Long Beach | California | 90806 | — |
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| University of Colorado | Denver | Colorado | 80262 | — |
| Advanced Neurosciences Research LLC | Fort Collins | Colorado | 80528 | — |
| Associated Neurologists of Southern CT PC | Fairfield | Connecticut | 06824 | — |
| Infinity Clinical Research | Hollywood | Florida | 33024 | — |
| University of Miami; Dept. of Neurology MS Center | Miami | Florida | 33136 | — |
| Neurological Services of Orlando | Orlando | Florida | 32806 | — |
| Lovelace Scientific Resources | Sarasota | Florida | 34292 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Atlanta Neuroscience Institute | Atlanta | Georgia | 30327 | — |
| Josephson Wallack Munshower Neurology PC | Indianapolis | Indiana | 46256 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| MidAmerica Neuroscience Institute | Prairie Village | Kansas | 66206 | — |
| Associates in Neurology PSC | Lexington | Kentucky | 40513 | — |
| Dragonfly Research, LLC | Wellesley | Massachusetts | 02481 | — |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109-0666 | — |
| Wayne State University; Department of Neurology | Detroit | Michigan | 48201 | — |
| The Minneapolis Clinic of Neurology | Golden Valley | Minnesota | 55422 | — |
| Rutgers New Jersey Medical School | Newark | New Jersey | 07103 | — |
| Holy Name Hospital | Teaneck | New Jersey | 07666 | — |
| MS Comprehensive Care Center | Teaneck | New Jersey | 07666 | — |
| Shore Neurology | Toms River | New Jersey | 08755 | — |
| Empire Neurology, PC | Latham | New York | 12210 | — |
| Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr | New York | New York | 63110 | — |
| South Shore Neurologic Associates P.C. | Patchogue | New York | 11772 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| SUNY at Stony Brook | Stony Brook | New York | 11790 | — |
| The Neurological Institute PA | Charlotte | North Carolina | 28204 | — |
| Neurology Associates PA | Hickory | North Carolina | 28602 | — |
| Raleigh Neurology Associates | Raleigh | North Carolina | 27607-6520 | — |
| Columbus Neuroscience | Columbus | Ohio | 43801 | — |
| Abington Neurological Associates | Abington | Pennsylvania | 19001 | — |
| Absher Neurology PA | Greenville | South Carolina | 29607 | — |
| Neurology Clinic PC | Cordova | Tennessee | 38018 | — |
| Sibyl Wray MD Neurology PC | Knoxville | Tennessee | 37934 | — |
| Advanced Neurosciences Institute | Nashville | Tennessee | 37205 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390-0001 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Bhupesh Dihenia M.D. P.A. | Lubbock | Texas | 79410 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
| Integra Clinical Research, Llc | San Antonio | Texas | 78229 | — |
| Neurology Center of San Antonio | San Antonio | Texas | 78258 | — |
| Swedish Neuroscience Institute | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 117 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01412333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01412333 live on ClinicalTrials.gov.